item management s discussion and analysis of financial condition and results of operations the following section of this annual report on form k titled management s discussion and analysis of financial condition and results of operations contains statements that are not statements of historical fact and are forward looking statements within the meaning of the federal securities laws 
these statements involve known and unknown risks  uncertainties  and other factors that may cause our actual results  performance  or achievement to differ materially from anticipated results  performance  or achievement  expressed or implied in such forward looking statements 
these statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties 
we discuss many of these risks and uncertainties at the beginning of this annual rep ort on form k and under item business and item a risk factors 
the following discussion should also be read in conjunction with the consolidated financial statements of anika therapeutics  inc and the notes thereto appearing elsewhere in this report 
management overview anika therapeutics  inc anika  and together  with its subsidiaries  the company develops  manufactures and commercializes therapeutic products for tissue protection  healing  and repair 
these products are based on hyaluronic acid ha  a naturally occurring  biocompatible polymer found throughout the body 
due to its unique biophysical and biochemical properties  ha plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints  the maintenance of the structural integrity of tissues  and the transport of molecules to and within cells 
see item business in this form k for details regarding the company s currently manufactured and marketed products 
on december   anika entered into a sale and purchase agreement the purchase agreement with fidia farmaceutici spa  a privately held italian corporation the seller pursuant to which the company acquired of the issued and outstanding stock of fidia advanced biopolymers srl  a privately held italian corporation fab for a purchase price consisting of million in cash and  shares of the company s common stock valued at million based on the closing stock price of per share 
fab s operating results and cash flow changes were immaterial for the one day of post acquisition activity 
see 
